Otsuka/Lundbeck’s Rexulti Has Time To Build A Lead In The Alzheimer’s Agitation Market

The US FDA approved Rexulti as the first drug for agitation in Alzheimer’s disease, a multibillion-dollar market where Lundbeck estimates it could bring in $1bn in annual sales.